Encyclopedia of

Feverfew (Tanacetum parthenium) 217
and Modern Medicines; Gorrad, J.W., Gibson,
G.G., Mitchard, M., Eds.; Ellis Horwood:
London, 1986; 100–104.
30. Wagner, H.; Fessler, B.; Lotter, H.; Wray, V.
New chlorine-containing sesquiterpene lactones
from Chrysanthemum parthenium. Planta Med.
1999, 51, 417–423.
31. Kuritzky, A.; Elhacham, Z.; Yerushalmi, Z.;
Hering, R. Feverfew in the treatment of migraine:
its effect on serotonin uptake and platelet
activity. Neurology 1994, 44 (Suppl. 2), 293 P
(Abstract).
32. Jadad, A.R.; Moore, R.A.; Carrol, D.; Jenkinson,
C.; Reynolds, D.J.M.; Gavaghan, D.J.; McQuay,
H.J. Assessing the quality of reports of randomized
clinical trials. Is blinding necessary?
Controlled Clin. Trials 1996, 17, 1–12.
33. Vogler, B.K.; Pittler, M.H.; Ernst, E. Feverfew as
a preventive treatment for migraine: a systematic
review. Cephalalgia 1998, 18, 704–708.
34. De Weerdt, C.J.; Bootsma, H.P.R.; Hendriks, H.
Herbal medicines in migraine prevention. Phytomedicine
1996, 3 (3), 225–230.
35. Johnson, E.S.; Kadam, N.P.; Hylands, D.M.;
Hylands, P.J. Efficacy of feverfew as prophylactic
treatment of migraine. Br. Med. J. 1985, 291,
569–573.
36. Murphy, J.J.; Heptinstall, S.; Mitchell, J.R.A.
Randomised double-blind placebo-controlled
trial of feverfew in migraine prevention. Lancet
1988, 189–192.
37. Palevitch, D.; Earon, G.; Carasso, R. Feverfew
(Tanacetum parthenium) as a prophylactic
treatment for migraine: a double-blind placebocontrolled
study. Phytother. Res. 1997, 11,
508–511.
38. Pfaffenrath, V.; Diener, H.C.; Fischer, M.; Friede,
M.; Heinnecke-von Zepelin, H.H. The efficacy
and safety of Tanacetum parthenium (feverfew)
in migraine prophylaxis—a double-blind,
multicentre, randomized placebo-controlled
dose–response study. Cephalalgia 2002, 22,
523–532.
39. Friede, M. Personal communication.
40. Pattrick, M.; Heptinstall, S.; Doherty, M. Feverfew
in rheumatoid arthritis: a double blind,
placebo controlled study. Ann. Rheum. Dis.
1989, 48, 547–549.
41. Heptinstall, S. Personal communication.
42. Awang, D.V.C. Feverfew effective in migraine
prevention. A research review. HerbalGram
1998, 42, 18.
43. Gardiner, A. Medicinal Herbs and Essential Oils;
Promotional Reprint Company Ltd.: London,
1996; 24.
44. Fenton, D.A.; Young, E.R.; Wilkinson, J.D.
Recurrent aphthous ulceration. Br. Med. J.
1983, 286, 1062 (Letter).
45. Hausen, B.M. Sesquiterpene lactones—
Tanacetum parthenium. In Adverse Effects of
Herbal Drugs; De Smet, P.A.G.M., Keller, K.,
Hänsel, R., Chandler, R.F., Eds.; Springer-
Verlag: Berlin, 1994; Vol. 1.
46. Murch, S.J.; Simmons, C.B.; Saxena, P.K. Melatonin
in feverfew and other medicinal plants.
Lancet 1997, 350, 1598–1599.
47. Anderson, D.; Jenkinson, P.C.; Dewdney, R.S.;
Blowers, S.D.; Johnson, E.S.; Kadam, N. Chromosomal
aberrations and sister chromatid
exchanges in lymphocytes and urine mutagenicity
of migraine patients: a comparison of chronicfeverfew
users and matched non-users. Hum.
Toxicol. 1988, 7, 145–152.
48. Hausen, B.M.; Osmundsen, P.E. Contact allergy
to parthenolide in Tanacetum parthenium (L.)
Schultz Bip. (feverfew, Asteraceae) and crossreactions
to related sesquiterpene lactone
containing Compositae species. Acta Dermato-
Venereol. (Stockh.) 1983, 63, 308–314.
49. Awang, D.V.C.; Fugh-Berman, A. Herb–drug
interactions in chronic conditions. Alternative
Ther. Women’s Health 2002, 4 (8), 57–60.
F